Fred Aslan sold $70k of ARTV
President and CEO at Artiva Biotherapeutics, Inc.. 25,500 shares at an average of $2.73, traded Aug 15, 2025, filed Aug 18, 2025.
Score components
- +25RoleCEO
- +8Trade size$70k at market
- 0Share of holdings soldSold 6.2% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -26.5%, 3m +13.2%, 6m +29.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-022224, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 15, 2025 | FTax withholding Common Stock10b5-1 | -4,472 | $2.13 | $9,525 | 412,193 | Aug 18, 2025 |
| Aug 15, 2025 | SOpen-market sale Common Stock10b5-1 | -25,500 | $2.73 | $70k | 386,693 | Aug 18, 2025 |
| Aug 15, 2025 | FTax withholding Common Stock10b5-1 | -4,472 | $2.75 | $12k | 382,221 | Aug 18, 2025 |
Related signals
Other insiders at Artiva Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | Artiva Biotherapeutics, Inc. | Fred Aslan Chief Executive Officer | $169k 23,463 shares | -2% | |
| 56Moderate | Artiva Biotherapeutics, Inc. | Fred Aslan Chief Executive Officer | $422k 61,696 shares | -4% | |
| 30Weak | Artiva Biotherapeutics, Inc. | Subhashis Banerjee Chief Medical Officer | $7,514 1,099 shares | -1% | |
| 42Moderate | Artiva Biotherapeutics, Inc. | Jennifer Bush COO, CLO, Compliance Officer | $57k 8,370 shares | -2% | |
| 38Weak | Artiva Biotherapeutics, Inc. | Christopher Horan Chief Tech Operations Officer | $71k 10,340 shares | -3% | |
| 33Weak | Artiva Biotherapeutics, Inc. | Fred Aslan Chief Executive Officer | $256k 23,429 shares | -2% | |
| 61Notable | Artiva Biotherapeutics, Inc. | Fred Aslan Chief Executive Officer | $690k 61,888 shares | -4% | |
| 30Weak | Artiva Biotherapeutics, Inc. | Subhashis Banerjee Chief Medical Officer | $12k 1,100 shares | -1% | |
| 45Moderate | Artiva Biotherapeutics, Inc. | Jennifer Bush COO, CLO, Compliance Officer | $94k 8,391 shares | -2% | |
| 40Moderate | Artiva Biotherapeutics, Inc. | Christopher Horan Chief Tech Operations Officer | $116k 10,366 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.